Table 1.
Baseline characteristics of patients with RA and healthy controls.
| Characteristics | RA(n=146) | HC(n=52) | P value |
|---|---|---|---|
| Demographics | |||
| Age, years, median (IQR) | 53.0 (43.0-65.3) | 51.0(43.3-57.5) | 0.157 |
| Gender, female, n (%) | 126 (86.3) | 45 (86.5) | 0.966 |
| Duration, years, median (IQR) | 6.3 (2.0-15.0) | ||
| TMS, minutes, median (IQR) | 3.0 (0-30.0) | ||
| Smoking, n (%) | 12 (8.2) | ||
| Clinical disease activity indicators, median (IQR) | |||
| TJC28 | 7.0 (3.0-13.3) | ||
| SJC28 | 3.0 (1.0-6.0) | ||
| PtGA | 4.5 (3.0-7.0) | ||
| PrGA | 4.5 (3.0-6.0) | ||
| Pain VAS | 4.0 (3.0-6.0) | ||
| HAQ | 0.6 (0.3-1.4) | ||
| DAS28-ESR | 5.0 (4.0-6.3) | ||
| DAS28-CRP | 4.6 (3.6-5.5) | ||
| SDAI | 22.4 (14.8-32.8) | ||
| CDAI | 19.0 (13.8-31.0) | ||
| Laboratory data | |||
| ESR (mm/h), median (IQR) | 37.5 (23.8-68.3) | ||
| CRP (mg/L), median (IQR) | 13.5 (3.8-32.0) | ||
| RF (IU/ml), median (IQR) | 86.8 (29.8-218.9) | ||
| RF positive, n (%) | 117 (80.1) | ||
| ACPA (U/ml), median (IQR) | 102.5 (2.9-200.0) | ||
| ACPA positive, n (%) | 108 (74.0) | ||
| X-ray of hands joints, median (IQR) | |||
| JE subscore | 25.5 (5.0-69.3) | ||
| JSN subscore | 16.0 (7.0-44.0) | ||
| mTSS | 42.0 (13.8-111.3) | ||
| Treatment, n (%) | |||
| Glucocorticosteroids | 55 (37.7) | ||
| csDMARDs | 85 (58.2) | ||
| Methotrexate | 62 (42.5) | ||
| Leflunomide | 30 (20.5) | ||
| Hydroxychloroquine | 21 (14.4) | ||
| Iguratimod | 23 (15.8) | ||
| bDMARDs | 15 (10.3) | ||
28TJC, 28-joint tender joint count; 28SJC, 28-joint swollen joint count; PtGA, patient global assessment of disease activity; PrGA, provider global assessment of disease activity; Pain VAS, pain visual analogue scale; HAQ, Stanford health assessment questionnaire disability index; DAS28-CRP, disease activity score in 28 joints with four variables including CRP; DAS28-ESR, disease activity score in 28 joints with four variables including ESR; CDAI, clinical disease activity index; SDAI, disease activity was assessed with simplified disease activity index. ESR, erythrocyte sedimentation rate; CRP, C reactive protein; RF, rheumatoid factor; ACPA, Anti-citrullinated protein antibody; JE, joint erosion; JSN, joint space narrowing; mTSS score, Sharp/van der Heijde score; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; bDMARDs, biological disease-modifying anti-rheumatic drugs.